O'Halloran Jane A, Powderly William G, Spec Andrej
Division of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, MO.
Curr Clin Microbiol Rep. 2017 Jun;4(2):88-95. doi: 10.1007/s40588-017-0064-8. Epub 2017 Apr 17.
Cryptococcal disease is most often thought of in the context of HIV infection. Much of our knowledge of the disease originates from its management in the HIV-positive population over the last 30 years. While the majority of cases globally continue to occur in the setting of advanced HIV, is increasingly responsible for disease in HIV-negative populations including those considered normal hosts and these HIV-negative populations will be the focus of this review.
Currently available data indicated that significant differences exist in epidemiology, clinical presentation, management and outcomes of cryptococcal disease in HIV-negative populations when compared to those living with HIV.
Further research is required to improve our knowledge of cryptococcal disease in particular in HIV-negative cohorts so as to optimise management of the disease in the future.
隐球菌病通常在HIV感染的背景下被提及。我们对该疾病的许多认识源于过去30年对HIV阳性人群的治疗。虽然全球大多数病例仍发生在晚期HIV患者中,但隐球菌病在HIV阴性人群(包括那些被认为是正常宿主的人群)中导致疾病的情况越来越多,这些HIV阴性人群将是本综述的重点。
现有数据表明,与HIV感染者相比,HIV阴性人群中隐球菌病的流行病学、临床表现、治疗及预后存在显著差异。
需要进一步研究以增进我们对隐球菌病的了解,尤其是在HIV阴性队列中,以便未来优化该疾病的治疗。